Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 6/2015

01.06.2015 | Health Economics and Quality of Life (M Harrison, Section Editor)

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

verfasst von: Emma Harris, Ana Tiganescu, Sandy Tubeuf, Sarah Louise Mackie

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastro-intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.
Literatur
1.
Hench P. Effects of cortisone in the rheumatic diseases. Lancet. 1950;2(6634):483–4.PubMed
2.
Smolen, J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
3.
Sarnes E et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–32.CrossRefPubMed
4.
Kirkham JJ et al. Can a core outcome set improve the quality of systematic reviews?—a survey of the Co-ordinating editors of Cochrane review groups. Trials. 2013;14:21.CrossRefPubMedCentralPubMed
5.
Boers M et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67(7):745–53.CrossRefPubMed
6.
Chen YF et al. Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review. J Clin Epidemiol. 2014;67(12):1309–19.CrossRefPubMed
7.
Sheu HM et al. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136(6):884–90.CrossRefPubMed
8.
Schoepe S et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.CrossRefPubMed
9.
10.
Schäcke H, Döcke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.CrossRefPubMed
11.
Tiganescu A et al. 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest. 2013;123(7):3051–60.CrossRefPubMedCentralPubMed
12.
Kerscher MJ, Korting HC. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol. 1992;5(2):77–80.CrossRefPubMed
13.
Curtis JR et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–6.CrossRef
14.
Vinding GR et al. Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology. 2014;228(3):261–8.CrossRefPubMed
15.
Van der Goes MC et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913–9.CrossRefPubMed
16.
Storms WW, Theen C. Clinical adverse effects of inhaled corticosteroids: results of a questionnaire survey of asthma specialists. Ann Allergy Asthma Immunol. 1998;80(5):391–4.CrossRefPubMed
17.
Andrews RC et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 2002;87(12):5587–93.CrossRefPubMed
18.
Quondamatteo F. Skin and diabetes mellitus: what do we know? Cell Tissue Res. 2014;355(1):1–21.CrossRefPubMed
19.
Makrantonaki E, Zouboulis CC. Molecular mechanisms of skin aging: state of the art. Ann N Y Acad Sci. 2007;1119:40–50.CrossRefPubMed
20.
Aschoff R et al. Evaluation of the atrophogenic potential of hydrocortisone 1 % cream and pimecrolimus 1 % cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832–6.CrossRefPubMed
21.
Schoepe S, Schacke H, Asadullah K. Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol. 2011;3(3):175–9.CrossRefPubMedCentralPubMed
22.
Norsgaard H et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–29.CrossRefPubMedCentralPubMed
23.
Hooten J, Hall 3rd R, Cardones A. Updates on the management of autoimmune blistering diseases. Skin Ther Lett. 2014;19(5):1–6.
24.
Schacke H et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009;158(4):1088–103.CrossRefPubMedCentralPubMed
25.
26.
Nagareddy PR et al. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol. 2005;289(5):H2144–52.CrossRefPubMed
27.
Holmes CJ et al. Dynamic role of host stress responses in modulating the cutaneous microbiome: implications for wound healing and infection. Adv Wound Care (New Rochelle). 2015;4(1):24–37.CrossRef
28.
Da Silva JA et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–93. Epub 2005 Aug 17.CrossRefPubMedCentralPubMed
29.
30.
Brubaker AL et al. Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age. J Immunol. 2013;190(4):1746–57.CrossRefPubMedCentralPubMed
31.
Saag KG et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23.CrossRefPubMed
32.
van der Goes MC et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015–21.CrossRefPubMed
33.
Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract. 2013;63(610):e361–6.CrossRefPubMedCentralPubMed
34.
Carli L et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32(7):1071–3.CrossRefPubMed
35.
Prokofyeva E, Wegener A, Zrenner E. Cataract prevalence and prevention in Europe: a literature review. Acta Ophthalmologica. 2013;91(5):395–405.CrossRefPubMed
36.
37.
Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47(4):171–88.CrossRefPubMed
38.
Huscher D et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–24.CrossRefPubMed
39.
Hoes JN et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–7.CrossRefPubMedCentralPubMed
40.
Mosca M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269–74.CrossRefPubMedCentralPubMed
41.
Lane RJM, Mastaglia FL. Drug-induced myopathies in man. Lancet. 1978;312(8089):562–6.CrossRef
42.
Schakman O et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163–72.CrossRefPubMed
43.
Jover JA et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.CrossRefPubMed
44.
Mazlumzadeh M et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8.CrossRefPubMed
45.
Spiera RF et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.PubMed
46.
Gabriel SE et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873–8.CrossRefPubMed
47.
Khaleeli AA et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18(2):155–66.CrossRef
48.
Levin OS et al. Steroid myopathy in patients with chronic respiratory diseases. J Neurol Sci. 2014;338(1–2):96–101.CrossRefPubMed
49.
Hosono, O., et al. Quantitative analysis of skeletal muscle mass in patients with rheumatic diseases under glucocorticoid therapy—comparison among bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging. Modern Rheumatology, 2014. 25(2):1–7.
50.
51.
Pereira RMR, de Carvalho JF. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41–4.CrossRefPubMed
52.
LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardpulm Rehabil. 1997;17(2):76–84.CrossRef
53.
Horber FF et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985;61(1):83–8.CrossRefPubMed
54.
Hansen M et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713–8.CrossRefPubMedCentralPubMed
55.
Laan RF et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119(10):963–8.CrossRefPubMed
56.
Nikitovic M et al. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int. 2013;24(2):659–69.CrossRefPubMedCentralPubMed
57.
Rizzoli, R. and E. Biver, Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol, 2014.
58.••
Compston J et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75(4):392–6. Provides guidelines for the management of osteoporosis.
59.
Grossman JM et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.CrossRef
60.
Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.CrossRefPubMed
61.
Ton FN et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464–70.CrossRefPubMed
62.
den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011;13(3):233–40.CrossRef
63.
Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009;23(10):1525–31.CrossRefPubMed
64.
Albaum JM et al. Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol. 2014;21(3):e486–504.PubMed
65.
66.
Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78(11):748–56.CrossRefPubMed
67.
Unizony, S., et al. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford), 2015.
68.
Jamilloux Y et al. Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. PLoS ONE. 2013;8(7):e68713.CrossRefPubMedCentralPubMed
69.
Kirwan JR et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1415–21.CrossRefPubMed
70.••
Duru, N., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2013: 1–9. Provides EULAR recommendations for managing patients on medium-high-dose glucocorticoid therapy.
71.
Gruvstad E et al. Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test. Int J Clin Pharmacol Ther. 2014;52(1):15–26. doi:10.​5414/​CP201938.CrossRefPubMed
72.
Kazlauskaite R et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245–53.CrossRefPubMed
73.••
Liu D et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. Provides practical guidance for clinicians for monitoring and managing glucocorticoid-related adverse effects.
74.
75.
Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499–506.CrossRefPubMed
76.
Nwaneri, C., H. Cooper, and D. Bowen-Jones, Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease, 2013.
77.
Wassenberg S et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371–80.CrossRefPubMed
78.
van Everdingen AA et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1–12.CrossRefPubMed
79.
Ha Y et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus. 2011;20(10):1027–34.CrossRefPubMed
80.
Dasgupta B et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–90.CrossRef
81.
Dasgupta B et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7.CrossRef
82.
83.
Uddhammar A et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29(4):737–42.PubMed
84.
Aviña-Zubieta JA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology. 2013;52(1):68–75.CrossRefPubMed
85.
Mazzantini M et al. Adverse events during long-term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39(3):552–7.CrossRefPubMed
86.
Hafström I et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis—a randomized study. J Rheumatol. 2007;34(9):1810–6.PubMed
87.
Hafner F et al. Endothelial function and carotid intima-media thickness in giant-cell arteritis. Eur J Clin Investig. 2014;44(3):249–56.CrossRef
88.
Souverein PC et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65.CrossRefPubMedCentralPubMed
89.
Tomasson G et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160(2):73–80.CrossRefPubMedCentralPubMed
90.
Kirwan J et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):688–95.CrossRefPubMedCentralPubMed
91.
Bakker MF et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329–39.CrossRefPubMed
92.
Hoes JN et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–8.CrossRefPubMed
93.
Reynolds RM et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh type 2 diabetes study. Eur J Endocrinol. 2012;166(5):861–8.CrossRefPubMedCentralPubMed
94.
Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–7.CrossRefPubMed
95.
Ninan J et al. Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol. 2011;38(10):2215–7.CrossRefPubMed
96.
Nadkarni S et al. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res. 2014;114(2):242–8.CrossRefPubMed
97.
98.
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed
99.
Harrison MJ et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008;35(4):592–602.PubMed
100.
Buitinga L et al. Comparative responsiveness of the EuroQol-5D and short form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res. 2012;64(6):826–32.CrossRef
101.
Gaujoux-Viala C et al. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(9):1478–83.CrossRefPubMed
102.
Marra CA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.CrossRefPubMed
103.•
Moller A, Sartipy U. Long-term health-related quality of life following surgery for lung cancer. Eur J Cardiothorac Surg. 2012;41(2):362–7. Demonstrates EQ-5D is responsive to AEs.
104.
Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19(2):125–9.CrossRefPubMed
105.
NICE, Guide to the methods of technology appraisal 2013. Process and methods guides. 2013: London, UK.
106.
Heather EM et al. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-alpha drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. Pharmacoeconomics. 2014;32(2):109–34.CrossRefPubMed
Metadaten
Titel
The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy
verfasst von
Emma Harris
Ana Tiganescu
Sandy Tubeuf
Sarah Louise Mackie
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 6/2015
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0513-4

Weitere Artikel der Ausgabe 6/2015

Current Rheumatology Reports 6/2015 Zur Ausgabe

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda

Spondyloarthritis (MA Khan, Section Editor)

Looking Into the New ASAS Classification Criteria for Axial Spondyloarthritis Through the Other Side of the Glass

Orphan Diseases (B Manger, Section Editor)

Multicentric Reticulohistiocytosis: a Critical Review

Spondyloarthritis (MA Khan, Section Editor)

Revisiting MHC Genes in Spondyloarthritis

Orphan Diseases (B Manger, Section Editor)

Tumor-Induced Osteomalacia: an Up-to-Date Review

Health Economics and Quality of Life (M Harrison, Section Editor)

How Important Is Mode of Administration in Treatments for Rheumatic Diseases and Related Conditions?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise